Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Com… Read more
Market Cap & Net Worth: Novavax Inc (NVAX)
Novavax Inc (NASDAQ:NVAX) has a market capitalization of $1.64 Billion ($1.64 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6023 globally and #3450 in its home market, demonstrating a 1.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Novavax Inc's stock price $10.08 by its total outstanding shares 162935945 (162.94 Million).
Novavax Inc Market Cap History: 2015 to 2026
Novavax Inc's market capitalization history from 2015 to 2026. Data shows change from $27.34 Billion to $1.64 Billion (-22.88% CAGR).
Index Memberships
Novavax Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.16 Trillion | 0.12% | #21 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.06% | #171 of 976 |
|
NASDAQ Composite
IXIC
|
$33.26 Trillion | 0.00% | #706 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.09% | #109 of 263 |
Weight: Novavax Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Novavax Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Novavax Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.97x
Novavax Inc's market cap is 0.97 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
2.49x
Novavax Inc's market cap is 2.49 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.11 Billion | $15.35 Million | -$279.97 Million | 267.44x | N/A |
| 2017 | $4.04 Billion | $31.18 Million | -$183.77 Million | 129.61x | N/A |
| 2018 | $6.00 Billion | $34.29 Million | -$184.75 Million | 174.87x | N/A |
| 2019 | $648.49 Million | $18.66 Million | -$130.10 Million | 34.75x | N/A |
| 2020 | $18.17 Billion | $475.60 Million | -$427.50 Million | 38.20x | N/A |
| 2021 | $23.31 Billion | $1.15 Billion | -$1.74 Billion | 20.34x | N/A |
| 2022 | $1.67 Billion | $1.60 Billion | -$657.94 Million | 1.05x | N/A |
| 2023 | $782.09 Million | $556.38 Million | -$545.06 Million | 1.41x | N/A |
| 2024 | $1.31 Billion | $682.16 Million | -$187.50 Million | 1.92x | N/A |
| 2025 | $1.09 Billion | $1.12 Billion | $440.30 Million | 0.97x | 2.49x |
Competitor Companies of NVAX by Market Capitalization
Companies near Novavax Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Novavax Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Novavax Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Novavax Inc's market cap moved from $27.34 Billion to $ 1.64 Billion, with a yearly change of -22.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.64 Billion | +50.00% |
| 2025 | $1.09 Billion | -16.42% |
| 2024 | $1.31 Billion | +67.50% |
| 2023 | $782.09 Million | -53.31% |
| 2022 | $1.67 Billion | -92.81% |
| 2021 | $23.31 Billion | +28.30% |
| 2020 | $18.17 Billion | +2701.76% |
| 2019 | $648.49 Million | -89.18% |
| 2018 | $6.00 Billion | +48.39% |
| 2017 | $4.04 Billion | -1.59% |
| 2016 | $4.11 Billion | -84.98% |
| 2015 | $27.34 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Novavax Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.64 Billion USD |
| MoneyControl | $1.64 Billion USD |
| MarketWatch | $1.64 Billion USD |
| marketcap.company | $1.64 Billion USD |
| Reuters | $1.64 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.